Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study

Morbelli, Silvia; Piccardo, Arnoldo; Villavecchia, Giampiero; Dessi, Barbara; Brugnolo, Andrea; Piccini, Alessandra; Caroli, Anna; Frisoni, Giovanni B.; Rodriguez, Guido; Nobili, Flavio

doi:10.1007/s00259-009-1218-6

Cited by 100 publications

(66 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…İstatistiksel parametrik haritalama (SMP) yönteminin kullanıldığı 14 AH, 16 MCI hastasını içeren bir çalışmada; AH grubunda posterior singulat korteks, prekuneus, inferior parietal ve orta temporal loblarda hipometabolizma gözlenirken, MCI grubunda hipometabolizmanın posterior singulat girus ile sınırlı olduğu saptanmıştır (15). MCI'nın heterojen bir başlık olduğu bilinse de prospektif çalışmalar amnestik MCI'sı olup da sonradan AH gelişen hastaların erken evrede AH-benzeri bir glukoz hipometabolizması gösterdiğini belirtmişlerdir (16). FDG PET/BT primer demans tiplerinin ayırıcı tanısında da önemli bir role sahiptir.…”

Section: Alzheimer Hastalığında F-18 Fdg Pozitron Emisyontomografi/biunclassified

Nuclear Medicine Methods in Dementia

Budak¹,

Aydın²

2017

Nts

View full text Add to dashboard Cite

Section: Alzheimer Hastalığında F-18 Fdg Pozitron Emisyontomografi/biunclassified

Nuclear Medicine Methods in Dementia

Budak¹,

Aydın²

2017

Nts

View full text Add to dashboard Cite

“…A crucial issue is the finding of posterior cingulate hypometabolism aMCI patients who do not convert to AD after some years (from 1 to 2) of follow-up [20]. Nestor et al [21] have suggested that significant hypometabolism in the posterior cingulate is typical for all MCI patients, without a direct relationship to their future conversion.…”

Section: Fdg-pet Findings In Mild Cognitive Impairment (Mci) and Earlmentioning

confidence: 99%

[18F]FDG-PET as a Biomarker for Early Alzheimer`s Disease

Nobili¹,

Morbelli²

2010

TONMEDJ

Self Cite

View full text Add to dashboard Cite

[18 Fluorine]fluorodeoxiglucose-Positron Emission Tomgraphy ( 18 F FDG-PET) has gained a leading role in the diagnostic assessment of patients with cognitive complaints, notably Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD). Together with morphological Magnetic Resonance Imaging (MRI) and cerebrospinal fluid biomarker assays it allows early identification of subjects with neurodegeneration of the AD-type, which is crucial in view of effective disease-modifying drugs.[18F]FDG-PET identifies hypometabolic regions in posterior cingulate-precuneus, posterior lateral and medial temporal-parietal association cortex, and in lateral frontal cortex. Hypometabolism in posterior cingulate-precuneus may be found even in MCI patients not yet converted to AD after a reasonable follow-up time and thus it might be a marker of memory deficit rather than of AD conversion. As [18F]FDG-PET is sensitive to synaptic dysfunction and depletion, hypometabolic areas can be detected before atrophy is highlighted by MRI in the same regions. The interpretation of the pathophysiological meaning of hypometabolism is discussed also in view of the most recent theory on the brain 'default mode network'. In longitudinal 1-year studies, [18F]FDG-PET has been shown an adequate tool to detect metabolic deterioration in AD patients better than amyloid-PET. It has been proposed as a surrogate biomarker to evaluate the effect of disease-modifying drugs in AD with a five times higher power than the commonly used neuropsychological scales. A flow-chart on the clinical use of [18F]FDG-PET is proposed, in which it is strongly recommended in MCI patients with suspected neurodegeneration.

show abstract

“…In MCI patients, delayed episodic memory performance significantly correlated with hypometabolism in the frontal cortex (27). Comparison between the 2 MCI subtypes (amnestic and nonamnestic) showed temporal lobe hypometabolism in amnestic MCI subjects, possibly reflecting the conversion to AD (28,29). Glucose metabolism is a sensitive measure of change in cognition and functional ability both in AD and in MCI and has value in predicting future cognitive decline (30).…”

Section: Brain Glucose Metabolismmentioning

confidence: 99%

Target-Specific PET Probes for Neurodegenerative Disorders Related to Dementia

Kadir¹,

Nordberg²

2010

J Nucl Med

View full text Add to dashboard Cite

Dementia is a highly prevalent problem causing considerable disability and mortality and exacting great costs to individuals, their families, and society. The 4 most common neurodegenerative disorders that cause dementia-Alzheimer disease, frontotemporal dementia, dementia with Lewy bodies, and dementia in Parkinson disease-have different underlying etiologies and pathogenetic mechanisms. There is a great need for early diagnostic markers; functional brain imaging may therefore assist in the detection and differential diagnosis of dementia due to neurodegenerative diseases. Functional imaging such as PET allows in vivo imaging of functional brain activity indicating cerebral blood flow and cerebral glucose metabolism, and PET allows imaging of neurotransmitter activity, including that of the cholinergic, dopaminergic, and serotonergic systems. New PET neuroimaging tracers are being developed for detecting pathologic parameters such as amyloid plaque and microglial activity. The development of molecular imaging is important for early diagnosis of dementia, selection of patients for therapies, and evaluation of therapies.

show abstract

Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study

Abstract: The discordant topography between atrophy and hypometabolism reported in AD is already present at the aMCI stage. Posterior cingulate-precuneus hypometabolism seemed to be an early sign of memory deficit, whereas hypometabolism in the left temporal cortex marked the conversion to AD.

Cited by 100 publications

References 51 publications

Nuclear Medicine Methods in Dementia

Nuclear Medicine Methods in Dementia

[18F]FDG-PET as a Biomarker for Early Alzheimer`s Disease

Target-Specific PET Probes for Neurodegenerative Disorders Related to Dementia

Contact Info

Product

Resources

About